Spécialisé dans la santé animale, Elanco investit 35 millions d’euros pour l’extension de son site de production basé à Huningue dans le Haut-Rhin. Ce projet, qui doit voir le jour ...

On Wednesday, Novartis gave a more detailed look at long-awaited clinical data that the company believes will help secure a broad approval for a successor drug to its blockbuster gene therapy ...

No­var­tis re­leased two Phase 3 datasets on Wednes­day that show a new ver­sion of its gene ther­a­py Zol­gens­ma led to mo­tor func­tion im­prove­ments in pa­tients … ...

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the treatment of older patients with spinal muscular atrophy (SMA).

Nearly six years ago, the Food and Drug Administration approved Zolgensma, a Novartis gene therapy for the fatal neuron-wasting disease spinal muscular atrophy. It heralded a new era of genetic ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients. Six years ago, the FDA ...

Ltd. from making misleading claims about its copy of Novartis AG’s blockbuster heart drug Entresto but declined to stop the generic-drug maker from using “Novadoz” branding, for now. Judge Evelyn ...

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years Global drugmaker Novartis will lay off 427 employees who ...

Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...

Another wave of layoffs will impact Novartis‘ U.S. headquarters in New Jersey. In a filing with the state Department of Labor & Workforce Development, the East Hanover-based Swiss pharmaceutical ...

Novartis signed on to become the National Football League’s first-ever corporate pharmaceutical partner. As part of the new multi-year deal, the Swiss pharma giant said it aims to empower ...

TOKYO, March 17 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early ...